JWM
CPRX

JPL Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

JPL Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158 Hold
5
– – ﹤0.01% 1566
2026
Q1 		$124 Buy
+5
New +$119 ﹤0.01% 1451
2025
Q4 		– Sell
-5
Closed -$99 – 330
2025
Q3 		$99 Buy
+5
New +$103 ﹤0.01% 1168

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JPL Wealth Management's CPRX Position: Q2 2026 in Review

JPL Wealth Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 5 shares worth $158. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

JPL Wealth Management first reported a position in CPRX in Q3 2025 and has held it in 3 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • JPL Wealth Management held 5 shares of Catalyst Pharmaceutical worth $158 as of Q2 2026.
  • JPL Wealth Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #1566 holding.
  • JPL Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.